Transition Bio, Inc.

Just like our #technology, we are building a one-of-a-kind #team. Explore #career opportunities in the U.S. and UK by visiting our LinkedIn job board. #condensates #condensomics

We're #hiring a Machine Learning Intern! If you have a strong interest in image analysis and computer vision, then this could be the perfect opportunity to get some hands on experience at a fast-paced biotech. #MachineLearning #ComputerVision #Internship #Biotech #AI

We're looking for a talented scientist to join our team in Cambridge, UK. This is an exciting opportunity to contribute to cutting-edge science in an innovative and collaborative biotech. #Hiring #Biotechnology #ScienceCareers #CambridgeUK. Know anyone who might be interested?

During today's #AACR2025 poster presentation, we were excited to share that Transition Bio has developed potent, selective, and orally-bioavailable small molecule inhibitors of #YTHDC1, a targetable driver of #MYC-driven #AML & small cell lung cancer (#SCLC). Transition Bio is redefining drug discovery at the #molecular level. See the full presentation at https://lnkd.in/ekn9DjXP www.transitionbio.com #oncology #condensates

Looking forward to presenting on our lead program at AACR on Sunday! #AACR2025 #TransitionBio Shilpi Arora

Transition Bio is excited to present at this year's #AACR2025 Annual Meeting in Chicago. We'll be highlighting preclinical data for our frontrunner oncology program, YTHDC1, a first-in-class small molecule inhibitor program targeting MYC-driven cancers. Shilpi Arora (CSO) & Martin Kulander (COO) will be in attendance. Click here now to view the abstract: https://lnkd.in/emFCqBqS. Please visit www.transitionbio.com on April 27th for the full poster presentation.

Transition Bio is pleased to attend the 66th #AmericanSocietyofHematology Annual Meeting #ASH2024 from Dec. 7-10 in San Diego. Check out the exciting progress we have made on our frontrunner oncology program, YTHDC1, a first-in-class small molecule inhibitor program targeting MYC-driven cancers including #AcuteMyeloidLeukemia. Learn more about the target and our approach to #BiomolecularCondensate drug discovery ! Shilpi Arora will present the following poster on Saturday, Dec. 7th from 5:30-7:30pm:    Presentation 2207:  Selective Inhibition of the m6a RNA Reader, YTHDC1, As a Novel Therapeutic Strategy for MYC-Driven Acute Myeloid Leukemia    See the full poster presentation by visiting www.transitionbio.com on Monday, December 9.

Our recent work on predicting the composition of biomolecular condensates — cellular complexes that regulate key processes, such as signalling, gene expression and stress response — together with a comprehensive proteome-scale atlas of condensate composition has been published in Nature Communications. 🌟🔬 https://lnkd.in/gGbcisCF Exciting collaboration with multiple scientists across University of Cambridge, in particular Tuomas Knowles' group at the Department of Chemistry and Sarah Teichmann FMedSci FRS group at European Bioinformatics Institute | EMBL-EBI Wellcome Sanger Institute, and with Transition Bio, Inc. Thanks to University of Cambridge Yusuf Hamied Department of Chemistry for the coverage https://lnkd.in/gWdqP2c8 and for Schmidt Science Fellows for funding.💡